Molecular Biotechnology Services
PO Box 201
300 George Street
New Haven, CT 06511
Tel: 203.785.7869
Fax: 203.785.7919
microarrays@yale.edu
|
GeneChip Expression analysis experiments involve the following major steps:
1. Experimental Design: It is absolutely essential to plan and execute the experiments with utmost care. It is important to begin the planning of the microarray experiment with a proper question. The experimental model/system should be well-characterized or well-defined with an independent experimental verification. For example, if a growth factor was added which induces differentiation in 24-48 hours, but you are collecting RNA at three hours post-treatment, you should still check a parallel culture for verification that differentiation occurred at the 24-48 hours period. If possible, a quick check for a gene that is known to be affected by the treatment should be performed. It is recommended that all experimental treatments be carried out in triplicates to compensate for biological and experimental variation. In vitro experiments using cultured cells should be conducted three different times (not three replicates performed on the same day) strictly following the same experimental procedures. Tumor specimens should be devoid of adjacent tissues and if possible, microdissected to obtain as pure a tumor sample as possible. Cell populations may also be further purified using cell-sorting techniques such as FACS. Dead cells also should be removed by density centrifugation. For comparative gene expression analysis, it is essential that all the experimental conditions such as temperature, CO2, media, reagents, and sample processing be kept identical for all samples. 2. RNA isolation: The quality of the RNA is the single most important determinant of a successful GeneChip analysis assay. Particularly, differential degradation of RNA can lead to erroneous conclusions about both the relative and absolute mRNA levels in the specimens. Although either mRNA or total RNA can be used as starting material, we prefer total RNA for two reasons: (1) isolating total RNA is easier and more economical than isolating mRNA and (2) there is loss of starting material during mRNA purification and consequently more mRNA is required to achieve sensitivity similar to that of the total RNA. In addition, there may be differential loss of individual mRNAs. We recommend TRIzol reagent for isolation of total RNA from tissue specimens as well as cultured and blood cells. Total RNA isolated using TRIzol should be further purified using the Qiagen RNeasy cleanup procedure. The minimum amount of total RNA required for GeneChip analysis is 5 µg (When RNA amount is limiting, as little as 2 µg of total RNA could be used). The A260/A280 ratio should be at least 1.8 for pure RNA. The quality of RNA should also be assessed by agarose gel electrophoresis. The Bioanalyzer gel profile should exhibit a 28S band that is 2 times more intense than 18S ribosomal RNA (Figure 2). It is important that the total RNA is free of genomic DNA contamination. We have written Standard Operating Procedures for the isolation of total RNA using both TRIzol and Qiagen RNeasy methods. If genomic DNA contamination is present, it is essential to remove it by DNase treatment, a modification included in the RNeasy cleanup protocol. 3. Target (labeled cRNA) Preparation: High quality total RNA is used as starting material to obtain labeled cRNA. In the first step, single stranded cDNA is synthesized by reverse transcription using the poly (A) RNA present in the starting total RNA sample. Single stranded cDNA is then converted into double stranded cDNA and purified using the Affymetrix Cleanup Module. An in vitro transcription (IVT) reaction is then carried out overnight in the presence of biotinylated UTP and CTP to produce biotin-labeled cRNA from the double stranded cDNA. The resulting cRNA is fragmented in the presence of heat and Mg+2 before hybridization to the test array. Due to the high cost of cDNA and cRNA synthesis reactions, we use a very strict quality control measures during the target preparation procedures (Figure 1). At each step the quality of sample is accessed by Agilent Bioanalyzer (Figure 2). |